Stay informed on the latest in arthritis prevention, research, treatment and care with JointHealth™ express, Canada's trusted source for arthritis news. Delivered right to your inbox, this "breaking news" bulletin provides timely updates on key arthritis topics, including disease management, research breakthroughs, and treatment advancements. As the longest-running arthritis news source in Canada, JointHealth™ express provides you expert insights from patients and analysis from arthritis health care professionals to help you on your arthritis journey. Stay connected to the arthritis information that matters most.
Click here to see JointHealth™ express bulletins from 2023 and earlier.
Latest News
Arthritis At Home 317 – The 2026 Canadian Rheumatology Association Annual Scientific Meeting
A new way to take anifrolumab approved in Canada for lupus
Health Canada has approved a new way for people living with lupus to take anifrolumab, a medication used to treat ...
Arthritis At Home 316 – Development of national clinical guidelines for transition in rheumatology
Arthritis Action Now: A national plan to change the future of arthritis in Canada
Arthritis At Home 315 – #CRArthritis: Showcasing research highlights from Canadian Rheumatology Association (CRA) and Arthritis Health Professions Association (AHPA) Annual Scientific Meeting
Arthritis At Home – Cost of juvenile arthritis to patients and families
New blog post from Joint Journeys, life with arthritis by Carrie: Waves
Arthritis At Home 314 – Tools and tips for a smooth transition from juvenile to adult arthritis care
#CRArthritis 2026 – The Halifax Edition!
Call for patient input on ruxolitinib (Opzelura®) for atopic dermatitis
Canada’s Drug Agency (CDA-AMC) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s ...
Arthritis At Home 313 – Australian Patient Advocacy Alliance partners on launch of Patients and patents campaign
Call for patient input on inebilizumab (Uplizna®) for immunoglobulin G4-related disease
Canada’s Drug Agency (CDA-AMC) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s ...
